Agenus is a biotechnology business based in the US. Agenus shares (AGEN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.67 – a decrease of 3.61% over the previous week. Agenus employs 389 staff and has a trailing 12-month revenue of around $160.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.67 |
|---|---|
| 52-week range | $2.50 - $19.69 |
| 50-day moving average | $4.65 |
| 200-day moving average | $9.45 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-11.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.57 from 2024-11-19
| 1 week (2024-11-14) | -7.22% |
|---|---|
| 1 month (2024-10-21) | -42.89% |
| 3 months (2024-08-21) | -50.48% |
| 6 months (2024-05-21) | -76.89% |
| 1 year (2023-11-21) | 277.39% |
|---|---|
| 2 years (2022-11-21) | -95.62% |
| 3 years (2021-11-19) | 68.4951 |
| 5 years (2019-11-21) | 80.467 |
| Revenue TTM | $160.4 million |
|---|---|
| Gross profit TTM | $82.6 million |
| Return on assets TTM | -21.95% |
| Return on equity TTM | -1278.83% |
| Profit margin | -141.9% |
| Book value | $-13.48 |
| Market Capitalization | $60.3 million |
TTM: trailing 12 months
We're not expecting Agenus to pay a dividend over the next 12 months.
Agenus's shares were split on a 1:20 basis on 11 April 2024 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Agenus shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Agenus shares which in turn could have impacted Agenus's share price.
Over the last 12 months, Agenus's shares have ranged in value from as little as $2.5 up to $19.688. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agenus's is 1.386. This would suggest that Agenus's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Agenus Inc. , a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.